Press release
Blepharitis Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Akorn Inc., Allergan Plc, Bausch Health Companies, Novartis, Pfizer Inc., Nicox
The Blepharitis Market Forecast report offers an in-depth understanding of the Blepharitis, historical and forecasted epidemiology as well as the Blepharitis market trends in the 7MM.DelveInsight's "Blepharitis Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Blepharitis, historical and forecasted epidemiology as well as the Blepharitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Blepharitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Blepharitis Market Forecast [https://www.delveinsight.com/sample-request/blepharitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Blepharitis Market Report:
*
The Blepharitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
*
In July 2023, The US Food and Drug Administration (FDA) has granted approval for Tarsus Pharmaceuticals' Xdemvy as a treatment for Demodex blepharitis. This marks a significant milestone as it is the first-ever FDA approval for a drug specifically targeting this eyelid condition. Before this approval, tea tree oil was commonly used to treat Demodex blepharitis. However, tea tree oil had its own safety concerns, particularly at higher concentrations. With the approval of Xdemvy, patients may have a new and potentially more effective option for managing this condition. The treatment is expected to be available for prescription by the end of August.
*
According to the American Academy of Ophthalmology (2023), blepharitis was detected in 37% to 47% of patients in the United States who were seen by respondents
*
Demodex blepharitis can afflict people of all ages, according to a study by John Meyer (2022), and its prevalence rises with age, affecting more than 80% of people over the age of 60 and 100% of those over the age of 70
*
According to the Atlas study (2022), 51% of patients have had demodex blepharitis symptoms for more than 4 years, and 58% of patients have never had a blepharitis diagnosis
*
More than 50% of individuals under the age of 18 in a research by Stanley et al. (2022) reported having blepharitis symptoms for four or more years. About 47% of people stated they were constantly aware of their eyes, and 23% said they worried about their eyes constantly
*
Key Blepharitis Companies: Akorn Inc., Allergan Plc, Bausch Health Companies, Inc., Novartis AG and Pfizer Inc., Nicox Ophthalmics, Inc., Laboratoires Thea, Sun Pharmaceutical, LianBio LLC, Merck Sharp & Dohme, AxeroVision, Inc., Alcon Research, Ursapharm Arzneimittel, Galderma R&D, Kala Pharmaceuticals, and others
*
Key Blepharitis Therapies: TP-03, PMP2207, Erythromycin, NCX 4251, Azithromycin, Fluticasone Propionate, ISV-502, Lotilaner, AzaSite Registered , AXR-270, Tobradex ST, Posiformin, COL-101, KPI-121, Moxifloxacin, and others
*
The Blepharitis epidemiology based on age-specific cases analyzed that Blepharitis is more common in individuals older than the age of 50
*
The Blepharitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Blepharitis pipeline products will significantly revolutionize the Blepharitis market dynamics.
Blepharitis Overview
Blepharitis is an inflammation of the eyelids. It typically affects both eyes along the edges of the eyelids.
Get a Free sample for the Blepharitis Market Report:
https://www.delveinsight.com/report-store/blepharitis-market [https://www.delveinsight.com/report-store/blepharitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Blepharitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Blepharitis Epidemiology Segmentation:
The Blepharitis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
*
Total Prevalence of Blepharitis
*
Prevalent Cases of Blepharitis by severity
*
Gender-specific Prevalence of Blepharitis
*
Diagnosed Cases of Episodic and Chronic Blepharitis
Download the report to understand which factors are driving Blepharitis epidemiology trends @ Blepharitis Epidemiology Forecast [https://www.delveinsight.com/sample-request/blepharitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Blepharitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Blepharitis market or expected to get launched during the study period. The analysis covers Blepharitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Blepharitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Blepharitis Therapies and Key Companies
*
TP-03: Tarsus Pharmaceuticals
*
PMP2207: Premark Pharma
*
Erythromycin: Bausch & Lomb Incorporated
*
TP-03: Tarsus Pharmaceuticals, Inc.
*
NCX 4251: Nicox Ophthalmics, Inc.
*
Azithromycin: Laboratoires Thea
*
Fluticasone Propionate: Nicox Ophthalmics, Inc.
*
ISV-502: Sun Pharmaceutical
*
Lotilaner: LianBio LLC
*
AzaSite Registered : Merck Sharp & Dohme
*
AXR-270: AxeroVision, Inc.
*
Tobradex ST: Alcon Research
*
Posiformin: Ursapharm Arzneimittel
*
COL-101: Galderma R&D
*
KPI-121: Kala Pharmaceuticals
*
Moxifloxacin: Alcon Research
Discover more about therapies set to grab major Blepharitis market share @ Blepharitis Treatment Market [https://www.delveinsight.com/sample-request/blepharitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Scope of the Blepharitis Market Report
*
Study Period: 2019-2032
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Blepharitis Companies: Akorn Inc., Allergan Plc, Bausch Health Companies, Inc., Novartis AG and Pfizer Inc., Nicox Ophthalmics, Inc., Laboratoires Thea, Sun Pharmaceutical, LianBio LLC, Merck Sharp & Dohme, AxeroVision, Inc., Alcon Research, Ursapharm Arzneimittel, Galderma R&D, Kala Pharmaceuticals, and others
*
Key Blepharitis Therapies: TP-03, PMP2207, Erythromycin, NCX 4251, Azithromycin, Fluticasone Propionate, ISV-502, Lotilaner, AzaSite Registered , AXR-270, Tobradex ST, Posiformin, COL-101, KPI-121, Moxifloxacin, and others
*
Blepharitis Therapeutic Assessment: Blepharitis current marketed and Blepharitis emerging therapies
*
Blepharitis Market Dynamics: Blepharitis market drivers and Blepharitis market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Blepharitis Unmet Needs, KOL's views, Analyst's views, Blepharitis Market Access and Reimbursement
To know more about Blepharitis companies working in the treatment market, visit @ Blepharitis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/blepharitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Blepharitis Market Report Introduction
2. Executive Summary for Blepharitis
3. SWOT analysis of Blepharitis
4. Blepharitis Patient Share (%) Overview at a Glance
5. Blepharitis Market Overview at a Glance
6. Blepharitis Disease Background and Overview
7. Blepharitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Blepharitis
9. Blepharitis Current Treatment and Medical Practices
10. Blepharitis Unmet Needs
11. Blepharitis Emerging Therapies
12. Blepharitis Market Outlook
13. Country-Wise Blepharitis Market Analysis (2019-2032)
14. Blepharitis Market Access and Reimbursement of Therapies
15. Blepharitis Market Drivers
16. Blepharitis Market Barriers
17. Blepharitis Appendix
18. Blepharitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=blepharitis-market-to-exhibit-rapid-growth-rate-during-the-forecast-period-20232032-investigates-delveinsight-akorn-inc-allergan-plc-bausch-health-companies-novartis-pfizer-inc-nicox]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Blepharitis Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Akorn Inc., Allergan Plc, Bausch Health Companies, Novartis, Pfizer Inc., Nicox here
News-ID: 3485865 • Views: …
More Releases from ABNewswire

Central Florida Notary Express, LLC Expands 24/7 Notary and Mobile Notary Servic …
Winter Park, FL - Central Florida Notary Express, LLC, a 24/7 provider of notary and mobile notary services and certified loan signings, announced expanded same-day coverage across the Greater Orlando area, including Orlando, Winter Park, Maitland, Casselberry, Winter Springs, DeLand, DeBary, Deltona, Sanford, and Lake Mary. The company offers on-site and curbside notarization for jurats, acknowledgments, power of attorney (POA), wills, health care surrogate forms, copy certifications, and real-estate loan…

Stafili Wine Cafe Brings the Heart of Greece to New York City - A Sophisticated …
Nestled in the vibrant neighborhoods of West Village and Tribeca, Stafili Wine Cafe is redefining New York's dining scene with an unforgettable Greek-inspired experience that blends exceptional wines, authentic Mediterranean cuisine, and an inviting, intimate atmosphere. Whether you're seeking a cozy date night, an after-work escape, or a refined venue for social gatherings, Stafili promises an indulgent journey through the flavors, aromas, and spirit of Greece - without ever leaving…

Solar Heroes Launches Premium Solar Control Window Film Solutions in Singapore, …
As Singapore continues to face soaring temperatures and rising energy costs, Solar Heroes, a premium solar control window film supplier and installer, is stepping up to deliver an innovative solution for homes, offices, and commercial spaces. With a commitment to sustainability, comfort, and performance, Solar Heroes is revolutionizing how Singaporeans experience indoor living through advanced solar control window film technology. More information can be found at https://solarheroes.sg.
Singapore - As Singapore…

Dlinxoutreach Unlocks the Power of AI Ecosystems for Companies Seeking Higher RO …
In today's fintech-driven digital economy, artificial intelligence is no longer a speculative technology; it is a monetizable growth driver. Global private investment in AI reached $252 billion in 2024, a 44.5% year-over-year increase according to Stanford's AI Index. In financial services, 77% of executives report achieving positive ROI within the first year of AI deployment, according to Bank Automation News. A Boston Consulting Group study further shows that one in…
More Releases for Blepharitis
Top Trends Transforming the Blepharitis Market Landscape in 2025: Targeted Anti- …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Blepharitis Industry Market Size Be by 2025?
The expansion of the blepharitis market has been exponential in the past few years. The market size is expected to surge from $0.86 billion in 2024 to $0.97 billion in 2025, with a compound annual growth rate (CAGR) of…
Blepharitis Drugs Market: An In-Depth Analysis
The global Blepharitis Drugs market was valued approximately $1.5 billion in 2023 and is projected to reach around $1.9 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 3.4% during the forecast period.
Blepharitis Drugs Market Overview
Blepharitis is an inflammatory condition of the eyelids, leading to symptoms such as redness, irritation, and crusting near the base of the eyelashes. The market's growth is driven by factors including…
Blepharitis Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Blepharitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Blepharitis Market, historical and forecasted epidemiology as well as the Blepharitis Market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Blepharitis Market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Blepharitis Market size from 2019 to 2032,…
Blepharitis Drugs Market Size, Share, Development by 2024
LP INFORMATION offers a latest published report on Blepharitis Drugs Market Analysis and Forecast 2019-2024 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Blepharitis Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular,…
Blepharitis Drugs Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Blepharitis Drugs Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Blepharitis Drugs players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Blepharitis Drugs with respect to individual growth…
Blepharitis Market Competitive Healthcare Assessment 2018 to 2025
Global Blepharitis Market Research Report 2018 tracks the major market events including product launches, technological developments, mergers & acquisitions, and the innovative business strategies opted by key market players. Along with strategically analyzing the key micro markets, the report also focuses on industry-specific drivers, restraints, opportunities and challenges in the Blepharitis market. This research report offers in-depth analysis of the market size (revenue), market share, major market segments, and different…